Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / By country / South Korea

Peptide legality · South Korea · updated 2026-09-22

Are peptides legal in South Korea?

Restricted

Peptides are legal in South Korea only as MFDS-approved prescription medicines (such as the GLP-1 peptide semaglutide/Wegovy®); unapproved 'research' peptides like BPC-157 and TB-500 have no MFDS approval and cannot be lawfully sold or prescribed for human use.

Legal status overview

Peptides are restricted in South Korea: approved peptide drugs are available only on a doctor's prescription, and unapproved peptides may not be legally marketed. The Ministry of Food and Drug Safety (MFDS) approves and classifies medicines, and approved peptide therapies such as semaglutide (Ozempic®/Wegovy®) are prescription-only injectables. Personal importation is governed by MFDS and the Korea Customs Service, which allow limited quantities of non-controlled prescription medicines with documentation while requiring advance approval for controlled substances.

Key points

  • In South Korea, approved peptide medicines are dispensed only on prescription, as shown by semaglutide products (Wegovy®) being classified as once-weekly injectable prescription drugs after Ministry of Food and Drug Safety (MFDS) approval. [1]
  • The Ministry of Food and Drug Safety (MFDS) is South Korea's national medicines regulator and controls which peptide drugs may be marketed, having approved Ozempic® (semaglutide) in May 2022, Wegovy® in April 2023, and Mounjaro® in June 2023 with a weight-management indication added in July 2024. [2]
  • In South Korea, legitimate GLP-1 peptide treatment requires a physician's prescription at a licensed clinic, and any product sold without a prescription is not genuine approved medication. [3]
  • South Korea restricted telemedicine (non-face-to-face) prescriptions for most obesity drugs after concerns about abuse and misuse of GLP-1 peptides were raised. [2]
  • South Korea's national health insurance service ran a 2023-2024 crackdown targeting off-label prescribing of Ozempic® for weight loss in non-diabetic patients, with prescribing physicians facing penalties. [3]
  • For personal importation into South Korea, travelers may bring up to six bottles (about a three-month supply) of non-controlled prescription medicine with original prescriptions and a doctor's letter, while controlled substances require advance import approval from the MFDS. [4]
  • Narcotic and psychotropic substances entering South Korea require advance import approval from the Ministry of Food and Drug Safety (MFDS) regardless of quantity, and applications should be filed online well before travel. [5]
  • No South Korean regulatory approval or lawful commercial pathway was found for 'research' peptides such as BPC-157 or TB-500, indicating they are unapproved products that cannot be legally sold for human use; this reflects inference from South Korea's prescription-drug framework rather than a peptide-specific statute. (no source found)

Compound-by-compound status

Semaglutide (GLP-1, Ozempic®/Wegovy®)Semaglutide is legal in South Korea as an MFDS-approved, prescription-only injectable, with Ozempic® approved in May 2022 and Wegovy® approved for weight loss in April 2023. [2]
Tirzepatide (Mounjaro®)Tirzepatide is legal in South Korea as an MFDS-approved prescription medicine, approved for glycemic control in June 2023 and for weight management in July 2024. [2]
BPC-157BPC-157 appears to be an unapproved research peptide in South Korea with no MFDS marketing authorization found, so it cannot lawfully be sold or prescribed for human use; this reflects inference from the general prescription-drug framework rather than a located BPC-157-specific source. (no source found)
TB-500 (thymosin beta-4)TB-500 appears to be an unapproved research peptide in South Korea with no MFDS approval found, meaning it has no lawful pathway for human sale or prescribing; this is inferred from the general framework rather than a TB-500-specific source. (no source found)
Human growth hormone (HGH/somatropin)Somatropin (HGH) is expected to be a prescription-only medicine in South Korea under MFDS controls, but no South Korea-specific source confirming its exact classification was located in this research. (no source found)

Frequently asked questions

Can I buy peptides in South Korea without a prescription?

No. In South Korea, approved peptide medicines such as GLP-1 drugs must be prescribed by a physician at a licensed clinic, and any peptide sold without a prescription is not a genuine approved product. [3]

Can I bring peptides into South Korea for personal use?

You may hand-carry up to about a three-month supply (up to six bottles) of a non-controlled prescription medicine into South Korea if you carry the original prescription and a doctor's letter; controlled substances require advance import approval from the MFDS. [4]

Can I get a peptide like Wegovy® prescribed by telemedicine in South Korea?

Generally no; South Korea restricted non-face-to-face (telemedicine) prescriptions for most obesity drugs, including GLP-1 peptides, in response to abuse and misuse concerns. [2]

Are there penalties for misusing GLP-1 peptides in South Korea?

Yes; South Korea's national health insurance service ran a 2023-2024 crackdown on off-label Ozempic® prescribing for weight loss in non-diabetic patients, and prescribing physicians can face penalties. [3]

Is BPC-157 legal in South Korea?

BPC-157 does not appear to have any MFDS approval in South Korea, so it is treated as an unapproved product with no lawful pathway for human sale or prescribing; this reflects the general prescription-drug framework rather than a BPC-157-specific rule. (no source found)

General information based on the sourced research above, not legal advice. Laws change and enforcement varies; for a specific situation in South Korea, consult a licensed attorney or the national regulator.